SML0150
Tolcapone
≥98% (HPLC), Catechol-O-methyltransferase inhibitor, powder
别名:
3,4-Dihydroxy-4′-methyl-5-nitrobenzophenone, Ro 40-7592
登录 查看组织和合同定价。
选择尺寸
关于此项目
经验公式（希尔记法）:
C14H11NO5
化学文摘社编号:
分子量:
273.24
UNSPSC Code:
12352200
PubChem Substance ID:
NACRES:
NA.77
MDL number:
产品名称
Tolcapone, ≥98% (HPLC)
SMILES string
Cc1ccc(cc1)C(=O)c2cc(O)c(O)c(c2)[N+]([O-])=O
InChI
1S/C14H11NO5/c1-8-2-4-9(5-3-8)13(17)10-6-11(15(19)20)14(18)12(16)7-10/h2-7,16,18H,1H3
InChI key
MIQPIUSUKVNLNT-UHFFFAOYSA-N
assay
≥98% (HPLC)
form
powder
storage condition
desiccated
color
yellow
solubility
DMSO: ≥15 mg/mL
originator
Roche
storage temp.
2-8°C
Quality Level
Gene Information
human ... COMT(1312)
正在寻找类似产品? 访问 产品对比指南
Application
Tolcapone may be used in COMT-mediated cell signaling studies.
Tolcapone has been used in methyltransferase assay in human embryonic kidney 293 cells.
Tolcapone has been used in methyltransferase assay in human embryonic kidney 293 cells.
Biochem/physiol Actions
Inhibition of catechol-O-methyltransferase by tolcapone increases the half-life and bioavailabilty of levodopa. It therefore is an effective adjunctive therapy in patients with Parkinson′s disease with motor response fluctuations.
Orally active catechol-O-methyltransferase (COMT) inhibitor: inhibits both central and peripheral COMT.
Tolcapone is an orally active catechol-O-methyltransferase (COMT) inhibitor. It inhibits both central and peripheral COMT. Tolcapone crosses the blood-brain barrier, and has been used for L-DOPA adjunct therapy in the treatment of Parkinson′s Disease.
Features and Benefits
This compound was developed by Roche. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
signalword
Warning
hcodes
pcodes
Hazard Classifications
Aquatic Acute 1
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
法规信息
新产品
此项目有
Mikael Palner et al.
Nuclear medicine and biology, 37(7), 837-843 (2010-09-28)
R-[(11)C]-SKF 82957 is a high-affinity and potent dopamine D(1) receptor agonist radioligand, which gives rise to a brain-penetrant lipophilic metabolite. In this study, we demonstrate that systemic administration of catechol-O-methyl transferase (COMT) inhibitors blocks this metabolic pathway, facilitating the use
Development of an HTRF assay for the detection and characterization of inhibitors of catechol-O-methyltransferase
Kimos M, et al.
Journal of Biomolecular Screening, 21, 490-495 (2016)
Jon E Grant et al.
The Journal of nervous and mental disease, 200(11), 996-998 (2012-11-06)
The course of pathological gambling (PG) in women has been described as having a later age of initiation but a shorter time to problematic gambling ("telescoped"). This study examined evidence for telescoping and its relationship with comorbidities. Seventy-one treatment-seeking individuals
Daniel D Truong
Clinical interventions in aging, 4, 109-113 (2009-06-09)
Levodopa has been the gold standard therapy for the motor symptoms of Parkinson's disease for more than three decades. Although it remains the most effective treatment, its long-term use is associated with motor fluctuations and dyskinesias that can be disabling
Colm M P O'Tuathaigh et al.
The international journal of neuropsychopharmacology, 15(9), 1331-1342 (2011-11-15)
Catechol-O-methyltransferase (COMT) is an important enzyme in the metabolism of dopamine and disturbance in dopamine function is proposed to be central to the pathogenesis of schizophrenia. Clinical epidemiological studies have indicated cannabis use to confer a 2-fold increase in risk
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持